LAS VEGAS, Sept. 20, 2018 /PRNewswire/ — Digipath, Inc. (DIGP), a service-oriented independent testing laboratory and media firm focused on the developing cannabis industry, was selected by CEOLIVE Media Group for a comprehensive video interview with its President and CEO, Todd Denkin.
Mr. Denkin had the opportunity to discuss Digipath’s growth in Nevada and plans for expansion into Northern California and internationally, as well as the future of cannabis from a data perspective.
Digipath Labs division has been finalizing ISO 17025 certification as this international standard has become mandatory for Nevada cannabis testing laboratories and in other jurisdictions around the country. ISO 17025 certification enables laboratories to demonstrate that they operate competently and generate valid results, thereby promoting confidence in their work.
Mr. Denkin mentions that year over year, Digipath Labs continues to grow its revenues as additional Nevada cultivation licenses are granted. An update on the lab being developed in Humboldt County, California was also provided during the interview, as Digipath expands into one of the largest cannabis markets in the world.
Digipath Labs has been adding key new members to its staff to provide pharmaceutical-grade analysis and to help maximize the quality of its clients’ products through research, development, and standardization.
Denkin says in the interview, “We always want to have the best scientists working on the best instrumentation in order to uphold the Digipath standard of high-quality testing, data acquisition, and analysis.”
Click here to watch the entire interview by CEOLIVE Media Group and Todd Denkin, President and CEO of Digipath Inc.
To find out more about Digipath and Digipath Labs, please visit:
About Digipath, Inc.
Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they make and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.